Clinical Trial

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck. The immunotherapy drugs involved in this study are: * Nivolumab (Opdivo™) * Lirilumab
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2017-11-09; most recent amendment 2025-06-16.
Status change: Completed → Active, Not Recruiting 2021-07-22
Status change: Recruiting → Completed 2021-01-19
Status change: Not Yet Recruiting → Recruiting 2018-03-28
Trial Details
NCT Number NCT03341936
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Bristol-Myers Squibb
Conditions Squamous Cell Carcinoma of the Head and Neck
Enrollment 29 participants
Start Date 2018-03-15
Primary Completion 2021-07-06 (estimated)
Study Completion 2026-07-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-18